Erika Hamilton: Not all AEs are equal…

Erika Hamilton shared a post by Hope Rugo on X/Twitter:

“Not all AEs are equal – neutropenia without increased infection rate or asymptomatic bradycardia may not matter much. Side effects like eye toxicity, stomatitis, etc can be much more disruptive. Just reporting rates of “G3 AEs” doesn’t tell the whole story in trials.”

Quoting Hope Rugo’s post:

“Nice discussion about impact of eye toxicity by H. Bonnefois. Really important toxicity of emerging targeted agents with huge patient impact. We are eval preventive strategies in I-SPY 2.”

Source: Erika Hamilton/Twitter and Hope Rugo/Twitter.

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective. Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.